Bruni C, Bitti R, Nacci F, Cometi L, et al. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. Clin Rheumatol 2021;40:85-91.
PMID: 32514676